MedTrace Logo

A Clinical Trial Designed to Evaluate the Safety and Efficacy Study of Luminate® in Inducing PVD (Posterior Vitreous Detachment) in Non-Proliferative Diabetic Retinopathy

NCT02435862 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 105

Last updated 2017-12-15

No results posted yet for this study

Summary

A Phase 2, Randomized, Double-masked, Placebo-controlled Multicenter Clinical Trial Designed to Evaluate the Safety and Efficacy of Luminate in Inducing PVD in Subjects with Non-Proliferative Diabetic Retinopathy.

Conditions

Interventions

DRUG

1.0mg Luminate®

DRUG

2.0mg Luminate®

DRUG

3.0mg Luminate®

OTHER

Balanced Salt Solution for intravitreal injection in 0.10cc

Sponsors & Collaborators

  • Duke University

    collaborator OTHER

  • Trial Runners, LLC

    collaborator OTHER

  • Allegro Ophthalmics, LLC

    lead INDUSTRY

Principal Investigators

  • Vicken Karageozian, MD · Medical monitor

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-02-01
Primary Completion
2017-08-10
Completion
2017-08-10

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02435862 on ClinicalTrials.gov